ArticleInfection and immunity2007
Exogenous farnesol interferes with the normal progression of cytokine expression during candidiasis in a mouse model.
Article in Infection and immunity, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 80 citations in OpenAlex.
- Lung Microbiota: From Healthy Lungs to Development of Chronic Obstructive Pulmonary Disease.International journal of molecular sciences · 2025Review
- The airway mycobiome and interactions with immunity in health and chronic lung disease.Oxford open immunology · 2024Review
- Farnesol remodels the peritoneal cavity immune environment influencingInfection and immunity · 2023Article
- Farnesol-Loaded Nanoliposomes Inhibit Inflammatory Gene Expression in Primary Human Skeletal Myoblasts.Biology · 2022Article
- Development of Carbazole Derivatives Compounds againstJournal of fungi (Basel, Switzerland) · 2021Article
- Farnesol contributes to intestinal epithelial barrier function by enhancing tight junctions via the JAK/STAT3 signaling pathway in differentiated Caco-2 cells.Journal of bioenergetics and biomembranes · 2019Article
- Endothelial nitric oxide synthase limits host immunity to control disseminated Candida albicans infections in mice.PloS one · 2019Article
- Nutrient and Stress Sensing in Pathogenic Yeasts.Frontiers in microbiology · 2019Review
- Potential Anti-Inflammatory and Anti-Cancer Properties of Farnesol.Molecules (Basel, Switzerland) · 2018Review
- Quorum sensing by farnesol revisited.Current genetics · 2017Review
- Article
- The Neuro-endocrinological Role of Microbial Glutamate and GABA Signaling.Frontiers in microbiology · 2016Review
- Article
- Imaging Candida Infections in the Host.Methods in molecular biology (Clifton, N.J.) · 2016Article
- Article
- In vitro interactions between farnesol and fluconazole, amphotericin B or micafungin against Candida albicans biofilms.The Journal of antimicrobial chemotherapy · 2015Article
- CD47 Promotes Protective Innate and Adaptive Immunity in a Mouse Model of Disseminated Candidiasis.PloS one · 2015Article
- Host-pathogen interaction and signaling molecule secretion are modified in the dpp3 knockout mutant of Candida lusitaniae.Infection and immunity · 2014Article
- Role of bacterial lipopolysaccharide in enhancing host immune response to Candida albicans.Clinical & developmental immunology · 2013Article
- Arachidonic acid metabolites in pathogenic yeasts.Lipids in health and disease · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida albicans, a dimorphic fungus composed of yeast and mycelial forms, is the most common human fungal pathogen. Th1 cytokines such as interleukin-2 (IL-2), gamma interferon (IFN-gamma), and tumor necrosis factor alpha (TNF-alpha), which are induced by macrophage IL-12, are critical to resistance against systemic candidiasis, while Th2 cytokines such as IL-4 and IL-5 are less critical. Farnesol is a quorum-sensing molecule produced by C. albicans that controls the formation of mycelia but is also a virulence factor. To determine whether farnesol enhances the virulence of C. albicans by modulating the production of Th1 and Th2 cytokines, mice were pretreated with farnesol prior to intravenous infection with a sublethal dose of farnesol-producing C. albicans. Production of IL-2, IL-4, IL-5, TNF-alpha, IFN-gamma, and IL-12 was evaluated by bead-array flow cytometry and enzyme-linked immunosorbent assay. Mice exhibited an elevation in serum TNF-alpha levels at 48 h and an elevation in IFN-gamma and IL-12 levels at 6 to 12 h after infection with C. albicans. Pretreatment with farnesol significantly reduced the elevation of both IFN-gamma and IL-12 but not TNF-alpha. In contrast, mice pretreated with farnesol exhibited an unexpected elevation in IL-5 levels. To determine whether farnesol has a direct effect on macrophage production of IL-12, peritoneal macrophages were pretreated with farnesol prior to stimulation with IFN-gamma plus lipopolysaccharide (LPS). Farnesol inhibited production of both IL-12 p40 and p70 from IFN-gamma/LPS-stimulated macrophages. Therefore, the role of farnesol in systemic candidiasis is likely due to its ability to inhibit the critical Th1 cytokines IFN-gamma and IL-12 and perhaps to enhance a Th2 cytokine, IL-5.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.